Dow Jones 10110.14 +69.32 1:06 pm PST, August 20, 2004  NASDAQ 1838.01 +18.12 For info, visit access.smallcapnetwork.com S & P 500 1098.37 +7.14 To be removed, please click here Russell 2000 547.64 +10.20 VOLUME 04: ISSUE 65  Feature: Biophan follow-up. Patent numbers really rise. Just before I embark on the annual family road-trip--back Wednesday-- a quick follow-up on nano biotech Biophan (OTCBB: BIPH). I don't usually do two pieces in a row on a company, but the relevant news flow out of NY-based Biophan is coming both fast and furious. On the heels of the company's announcement of a skookum development deal with NASA--noted here on Tuesday--investors jumped on board and moved the shares from the low 60-cent level to 80-odd cents by Friday.  Following a conference call Thursday, the trading volume continued to swell and the shares moved higher. CEO Mike Weiner deftly outlined the benefits to Biophan of the NASA deal and answered questions. It appears that listeners/investors liked what they heard. By following the links at www.trilogy-capital.com, the replay of Biophan's detailed and informative conference call can be accessed. Patently obvious. Equally compelling is that on Friday the company updated its patent portfolio numbers (release below). For those interested in the progress and ultimate profitability of Biophan, these patent numbers are key. The rapid growth and expansion of the patent portfolio is the currency through which shareholder value will be realized. And, we believe, the potential for licensing and joint venture deals--such as the one Biophan just struck with NASA-- will undoubtedly push the fortunes of the company forward, faster. For risk-oriented investors, Biophan looks a good bet to accumulate and add to the speculative end of a portfolio. We originally suggested a protective stop loss at 50 cents--that number should now be raised to 60-65 cents. The shares are volatile and the market, though it appears more buoyant of late, is telling us that in this environment, a prudent defensive strategy should still win out over blind faith. Nothing moves up in a straight line-- in case you hadn't noticed... 80 and counting, fast... The release below notes that Biophan's intellectual property portfolio now encompasses 80 issued and pending patents. That's a 30 percent increase in the 2nd quarter alone. The good news for investors is that these patents and licenses represent a world-class collection of nano- and bio -technologies that aren't simple airy-fairy esoteric applications that no one can understand.  These technologies are real-world solutions for serious therapeutic and diagnostic challenges that will enhance- if not revolutionize- patient care and will save the healthcare system a huge whack of dough--something we should all get behind. The sheer number and growth of its patent portfolio should see Biophan in commercialization with a number of technologies soon. Even then, the company's quest for more patents and technologies through R&D and acquisition will continue and, we believe, ultimately push Biophan further to the forefront as a leader in the field of nano- and biotechnology applications. I must reiterate that a trip to the company's website (www.biophan.com) to read about this stuff is well worth your time. As well, investors can keep up to date on Biophan's growing R&D relationship with medical device behemoth Boston Scientific (NYSE: BSX). The quality of the announcements this week, as well as a listen to the conference call should virtually force risk-oriented investors to have a serious look at both the compelling potential and expansive scope of Biophan. We'll keep you apprised. There, now I can hit the road.   Press Release Biophan Reaches Major Milestone in Intellectual Property; Expands Biomedical Technology Portfolio to Total of 80 Patents, Licenses or Applications Count Represents 30% Growth of Technology Portfolio in 2nd Quarter Rochester, NY, August 20, 2004 -- Biophan Technologies, Inc. (OTC BB: BIPH), a developer of next-generation biomedical technology, today announced that the company's technology portfolio has swelled to 80 different patents, and pending patent applications either owned by Biophan or its licensors. The portfolio of groundbreaking technologies represents the world's most significant collection of intellectual property focused upon extending the safety, functionality, and compatibility of vital biomedical devices with magnetic resonance imaging (MRI), one of medicine's most important diagnostic imaging tools. The announcement was made by Michael Weiner, president and CEO of Biophan.  The Company has expanded its advanced technology portfolio 30% in the last 3 months alone, and the steep rate of technology acquisition is continuing. Biophan's patents and licenses involve several cutting-edge fields of research and development, including nanotechnology and biothermal battery technology. "The future and success of Biophan lies in the commercialization of critically important and far-reaching science and technology. Biophan is at the forefront of this development," said Mr. Weiner. "It is extraordinary that we have been able to amass so much cutting-edge technology in such a short time, and we are excited by the vast market opportunities available for the products we're developing with this world-class portfolio of intellectual property." Our technology has the potential to impact millions of lives as biomedical devices are made safe for use with MRI, or are powered by biothermal batteries, or enhanced by drug delivery innovations. Biophan recently announced a joint development agreement with the NASA Ames Research Center for Nanotechnology, Moffet Field, CA, for the characterization and development of high-density, nano-engineered thermoelectric materials for use with implantable medical devices.  For more investor-specific information about Biophan, or to view streaming video of  Biophan's Michael Weiner and NASA's David Lackner announcing the agreement, go to Trilogy Capital's homepage at www.trilogy-capital.com.  About Biophan Technologies Biophan Technologies develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with magnetic resonance imaging (MRI) equipment. The Company develops enabling technologies for implanted medical systems such as pacemakers, and interventional surgical devices such as catheters and guidewires, as well as stents and other implants that can be safely and effectively imaged under MRI. The technology is also being used to create enhanced MRI contrast agents. Committed to growth through innovation and developmental leadership, Biophan and its licensors have 19 issued U.S. patents and 61 patents pending, in areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, biothermal batteries, and photonics. Biophan's technology will help realize its goal of one day making all biomedical devices capable of safely and successfully working with MRI. For more information, please visit www.biophan.com. Cautionary Statement Regarding Forward-Looking Statements  Certain statements included in this press release may constitute forward-looking statements.  Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's MRI technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.   Contact: Carolyn Hotchkiss Biophan Technologies, Inc. 585.214.2407  Press Interviews:  Michael Weiner  585.214.2441   We Value Your Feedback Got comments, questions or suggestions? Send 'em on over: Editor@smallcapnetwork.com If you wish to send a written request or inquiry, please send it to our physical address: TGR Group, LLC 3525 Del Mar Heights Rd #334 San Diego, CA 92130 Unsubscribe Here D I S C L A I M E R : The SmallCap Digest is an independent electronic publication committed to providing our readers with factual information on selected  publicly traded companies. SmallCap Digest is not a registered investment advisor or broker-dealer. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward  maximizing the upside potential for investors while minimizing the downside risk, whenever possible.  Moreover, as detailed below, this publication accepts compensation from third party consultants and/or companies which it features for the publication and circulation of the SmallCap Digest or representation on SmallCapNetwork.net.  Likewise, this newsletter is owned by TGR, LLC.  To the degrees enumerated herein,  this newsletter should not be regarded as an independent publication. Click Here to view our compensation on every company we have ever covered, or visit the following web address:  http://access.smallcapnetwork.com/compensation_disclosure.html for our full compensation disclosure and http://access.smallcapnetwork.com/short_term_alerts.html for Trading Alerts compensation and disclosure. TGR Group LLC has been paid a fee of $25,000 by Trilogy Capital for reporting on the Company. On August 16, 2004, the contract was renewed by Trilogy Capital for another $25,000. Additionally, Some of the companies featured in the SmallCap Digest Newsletter pay an ESP (Electronic Service Provider) fee to an affiliated Technology Company for electronic delivery of this newsletter and other web related technology services. Fees range from $3,000 to $5,000 per month. All statements and expressions are the sole  opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities  mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein. The editor, members of the editor's family, and/or entities with  which the editor is affiliated, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter. The profiles, critiques, and other editorial content of the SmallCap Digest and SmallCapNetwork.net may contain forward-looking statements relating to the expected capabilities of the companies mentioned herein. THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN  SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN  CONSENT OF THE EDITORS OF SMALLCAPNETWORK.NET. We encourage our readers to invest carefully and read the investor information available at the web sites of  the Securities and Exchange Commission ("SEC") at http://www.sec.gov and/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at  http://www.sec.gov/consumer/cyberfr.htm . Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.